Methadone-induced respiratory depression in a patient with a history of alcoholism

Journal of Palliative Medicine

Volumn 8, Issue 5, 2005, Pages 1062-1066

  Elsayem, Ahmed ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CELECOXIB; CIMETIDINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; FENTANYL; HYDROMORPHONE; LAXATIVE; LEVOTHYROXINE; MEGESTROL; METHADONE; MORPHINE; NALOXONE; NEFAZODONE; OXYCODONE; PROMETHAZINE; RIFAMPICIN; SERTRALINE;

AGED; ALCOHOLISM; ANXIETY; ARTICLE; CASE REPORT; CHRONIC PAIN; COGNITIVE DEFECT; COMA; DEPRESSION; DIARRHEA; DRUG SUBSTITUTION; HALLUCINATION; HUMAN; MALE; MALNUTRITION; MYOCLONUS; PARANOID SCHIZOPHRENIA; RESPIRATION DEPRESSION; RIGOR; SWEATING; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

AGED; ALCOHOLISM; ANALGESICS, OPIOID; BACK PAIN; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; MALE; MEDICATION ERRORS; METHADONE; RESPIRATORY INSUFFICIENCY; SERTRALINE;

EID: 27644571069     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2005.8.1062     Document Type: Article

References (30)

1. Bruera E: Symptom control in patients with cancer. J Psychosocial Oncology 1990;8:47-73.
2. Foley K: The treatment of cancer pain. N Engl J Med 1984;313:84-95.
3. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillain K: The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 1991;7:6-9.
4. Bruera E, Schoeller T, Wenk R, MacEachern T, Marcelino S, Hanson J, Suarez-Almazor M: A prospective multi-center assessment of the Edmonton Staging System for cancer pain. J Pain Symptom Manage 1995;10:348-355.
5. Ripamonti C, Zecca E, Bruera E: An update on the clinical use of methadone for cancer pain. Pain 1997;70:109-115.
6. Bruera E, Fainsinger R, Moore M, Thibault R, Spoldi E, Ventafridda V: Local toxicity with subcutaneous methadone: experience of two centers. Pain 1991; 45:141-143.
7. Sweeney C, Bruera E: New role for old drugs: Methadone. Prog Palliat Med 2001;9:8-10.
8. Iribarne C, Dreano Y, Bardou LG, Menez JF, Burthou F: Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997;117:13-23.
9. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, Beaune P, Menez JF: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-372.
10. Yoko T, Pereira J, Watanabe S: Methadone and fluconazole: Respiratory depression by drug interaction. J Pain Symptom Manage 2002;23:148-153.
11. Herrlin K, Segerdahl M, Gustafsson MS, Kalso E: Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000;356:2069-2070.
12. Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005;352:1112-1120.
13. Wilkinson GR: Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-2221.
14. Eap C, Bartschy G, Powell K, Baumann P: Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psycopharmacol 1997;17:113-117.
15. Hamilton SP, Nunes EV, Janal M, Weber L: The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000;9:63-69.
16. Marks C, Goldring R: Chronic hypercapnia during methadone maintenance. Am Rev Resp Dis 1973;108:1088-1093.
17. Santiago T, Pugliese A, Edelman N: Control of breathing during methadone addiction. Am J Med 1977;62:347-354.
18. Kloke M, Rapp M, Bosse B, Kloke O: Toxicity and /or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support care cancer 2000;6:479-486.
19. Gonzales G, Coyle N: Treatment of cancer pain in a former opioid abuser: Fears of the patient and staff and their influence on care. J Pain Symptom Manage 1992;7:246-249.
20. Moore R, Bone L, Geller B, Mamon JA, Stoku EJ, Levine DM: Prevalence, detection and treatment of alcoholism in hospitalized patients. JAMA 1989;261:403-407.
21. O'Brien CP, Eckardt MJ, Linoila V: Pharmacotherapy of alcoholism. In: Bloom F, Kupfer D (eds): Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995, pp. 1745-1755.
22. Berntzen D, Gotestam KD: Effects of on-demand versus fixed-interval schedules in the treatment of chronic pain with analgesic compounds. J Consult Clin Psychol 1987;55:213-217.
23. Chapman CR, Gavrin J: Suffering and its relationship to pain. J Palliat Care 1993;9:5-13.
24. Bruera E, Moyano J, Seifert L, Fainsinger RL, Hanson J, Suarez-Almazor M: The frequency of alcoholism among patients with pain due to terminal cancer. J Pain Symptom Manage 1995;10:599-603.
25. Fainsinger R, Schoeller T, Bruera E: Methadone in the management of cancer pain: A review. Pain 1993;52:137-147.
26. Hunt G, Bruera E: Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 1995;10:401-404.
27. Hendrie CA: Naloxone-sensitive hyperalgesia follows analgesia induced by morphine and environmental stimulation. Pharmacol, Biochem Behav 1989;32:961-966.
28. Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A: A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 2005;29:224-236.
29. Tempel A, Zukin R, Gardener E: Super sensitivity of brain opiate receptor subtypes after chronic naltrexone treatment. Life science 1982;31:1401-1404.
30. Jason J, Irvine R: Mechanism of fatal opioid dose. Addiction 1999;94:961-972.